• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BBNX

    Beta Bionics Inc.

    Subscribe to $BBNX
    $BBNX
    Medical/Dental Instruments
    Health Care

    IPO Year: 2025

    Exchange: NASDAQ

    Recent Analyst Ratings for Beta Bionics Inc.

    DatePrice TargetRatingAnalyst
    2/24/2025Buy
    BofA Securities
    2/24/2025$30.00Buy
    Lake Street
    2/24/2025$25.00Buy
    Stifel
    2/24/2025$26.00Overweight
    Piper Sandler
    2/24/2025$28.00Outperform
    Leerink Partners
    2/20/2025$20.00Neutral
    Ladenburg Thalmann
    2/20/2025$20.00Neutral
    Robert W. Baird
    See more ratings

    Beta Bionics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025

      IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025. First Quarter 2025 Financial Results & Key Metrics Net sales of $17.6 million, up 36% compared to $12.9 million in the first quarter of 2024. Durable Medical Equipment (DME) channel net sales of $13.8 million, up 14% compared to $12.1 million in the first quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $3.8 million, up 360% compared to $0.8 million in the first quarte

      5/6/25 4:02:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Present at the Bank of America Securities Health Care Conference

      IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the desig

      5/1/25 8:00:00 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

      IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c

      4/16/25 4:05:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Host Investor Event on June 22, 2025

      IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX) (the "Company"), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8:30 am Central Time (9:30 am Eastern Time). Members of the Company's management team, led by Sean Saint, President and CEO, will present at the event. The agenda will include updates on commercial a

      4/9/25 7:30:00 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025

      IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights & Key Metrics Net sales of $20.4 million, up 145% compared to $8.4 million in the fourth quarter of 2023. Durable Medical Equipment (DME) channel net sales of $18.1 million, up 127% compared to $7.9 million in the fourth quarter of 2023.Pharmacy Benefit Plan (PBP) channel net sales of $2.4 million, up 491% compared to $0.4 mil

      3/25/25 4:02:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

      IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived

      2/27/25 7:00:00 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

      IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters' option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by B

      1/31/25 5:56:42 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    Beta Bionics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Beta Bionics

      BofA Securities initiated coverage of Beta Bionics with a rating of Buy

      2/24/25 1:34:43 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Beta Bionics with a new price target

      Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00

      2/24/25 9:48:29 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Beta Bionics with a new price target

      Stifel initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $25.00

      2/24/25 7:03:36 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on Beta Bionics with a new price target

      Piper Sandler initiated coverage of Beta Bionics with a rating of Overweight and set a new price target of $26.00

      2/24/25 7:03:36 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Leerink Partners initiated coverage on Beta Bionics with a new price target

      Leerink Partners initiated coverage of Beta Bionics with a rating of Outperform and set a new price target of $28.00

      2/24/25 7:03:15 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Ladenburg Thalmann initiated coverage on Beta Bionics with a new price target

      Ladenburg Thalmann initiated coverage of Beta Bionics with a rating of Neutral and set a new price target of $20.00

      2/20/25 8:18:30 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Beta Bionics with a new price target

      Robert W. Baird initiated coverage of Beta Bionics with a rating of Neutral and set a new price target of $20.00

      2/20/25 6:58:48 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    Beta Bionics Inc. Financials

    Live finance-specific insights

    See more
    • Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

      IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c

      4/16/25 4:05:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

      IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived

      2/27/25 7:00:00 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    Beta Bionics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      2/3/25 8:30:15 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      2/3/25 4:49:52 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    Beta Bionics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Michel Gerard J was granted 12,547 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/27/25 7:04:55 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Michel Gerard J

      3 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/27/25 7:00:25 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Director Lezack Adam was granted 11,247 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/18/25 8:00:11 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Director Jones Christy was granted 11,247 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/18/25 8:00:15 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Director Palasis Maria was granted 11,247 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/18/25 8:00:12 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Director Dearen Danny L. was granted 11,247 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/18/25 8:00:12 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Director Carney Sean was granted 11,247 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/18/25 8:00:08 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Feider Stephen was granted 47,000 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/3/25 5:45:08 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Hopman Mark was granted 35,000 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/3/25 5:45:15 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • President & CEO Saint Sean was granted 108,000 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/3/25 5:45:05 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    Beta Bionics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care

    Beta Bionics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Beta Bionics Inc.

      10-Q - Beta Bionics, Inc. (0001674632) (Filer)

      5/6/25 4:20:28 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Beta Bionics, Inc. (0001674632) (Filer)

      5/6/25 4:03:09 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Beta Bionics Inc.

      10-K/A - Beta Bionics, Inc. (0001674632) (Filer)

      3/28/25 4:05:42 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Beta Bionics, Inc. (0001674632) (Filer)

      3/27/25 4:45:53 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Beta Bionics Inc.

      10-K - Beta Bionics, Inc. (0001674632) (Filer)

      3/25/25 5:00:43 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Beta Bionics, Inc. (0001674632) (Filer)

      3/25/25 4:03:11 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Beta Bionics Inc.

      SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)

      2/7/25 1:44:24 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Beta Bionics Inc.

      SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)

      2/5/25 5:59:39 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Beta Bionics Inc.

      S-8 - Beta Bionics, Inc. (0001674632) (Filer)

      2/3/25 6:03:40 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Beta Bionics Inc.

      8-K - Beta Bionics, Inc. (0001674632) (Filer)

      1/31/25 5:10:12 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care